Cutaneous T-Cell Lymphoma
Among the Nation's Best for Cancer
U.S. News has named Jefferson among the best hospitals in the nation for Cancer care.
If you are diagnosed with cutaneous T-cell lymphoma (CTCL), a type of non-Hodgkin's lymphoma, the experienced team of Jefferson Health's Cutaneous Lymphoma Center provides a multidisciplinary approach to guide you through available treatment options that address all your medical, emotional and spiritual needs.
Most patients with cutaneous lymphoma notice a red rash on the skin that does not go away. This condition can often be misdiagnosed or commonly mistaken for inflammatory, chronic skin conditions such as psoriasis or eczema. Symptoms of cutaneous T-cell lymphomas may include:
- Red, scaly patches of skin that are itchy and peel
- Small, pimple-like lesions on the skin
- Thickened patches of skin resembling eczema
- Large lumps just under the skin
Having symptoms does not mean you have cutaneous lymphoma. If you have symptoms, tell your doctor, especially if symptoms are severe or have continued for longer than a few weeks.
Treatment Options for Cutaneous T-cell Lymphoma
Bringing together the expertise of Jefferson dermatologists, pathologists, medical oncologists, radiation oncologists and nurses, your medical team will give a thorough evaluation and devise a personalized treatment plan based on the nature of your cancer and its progression. Your team will help you weigh the benefits and risks of each treatment, so you can choose the option that is best for you, including:
- Allogeneic transplant
- Phototherapy (narrow band UVB)
- Skin-directed therapies
- Targeted immunologic therapies
- Total skin electron beam therapy
Advanced Cases of Cutaneous T-cell Lymphoma
In advanced cases, physicians may perform bone marrow stem cell transplantation to replace cells damaged by chemotherapy with healthy ones. Specialists within Jefferson's transplant program are pioneering efforts to reduce complications of transplant procedures, such as a potentially fatal reaction called graft-versus-host disease (GVHD) in which the donor marrow attacks its new host.
The standard method for preventing GVHD, which involves delivering chemotherapy drugs prior to transplantation, can weaken the immune system, which may cause infections and even secondary cancers. Through this novel procedure developed at Jefferson, chemotherapy drugs are administered after the introduction of T cells but before stem cells are given. As a result, GVHD-causing cells are killed, while sparing cells that restore the immune system. In clinical trials, this approach is bringing individuals lacking well-matched donors quicker, broader access to transplants with better results.
Make an Appointment
Call the Cutaneous Lymphoma Center at 215-955-9295 or 1-800-JEFF-NOW (1-800-533-3669) to make an appointment.